Novel Spectrophotometric Methods for Simultaneous Determination of Rosuvastatin Calcium, Timolol Maleate and Diclofenac Sodium in Pharmaceutical Ternary Mixture and Spiked Human Plasma

Mohamed E. M. Hassouna[1*] and Hafsa O. Salem[1]

[1]*Department of Chemistry, Faculty of Science, 62514, Beni-Suef University, Beni-Suef, Egypt.*

Authors' contributions

This work was carried out in collaboration between both authors. Author MEMH designed the study, performed the statistical analysis, wrote the protocol, wrote the first draft of the manuscript and managed the revisions. Author HOS managed the analyses of the study and managed the literature searches. Both authors read and approved the final manuscript.

Original Research Article

ABSTRACT

Three sensitive, times saving, precise and accurate spectrophotometric techniques have been established and confirmed for the simultaneous determination of ternary admixture of rosuvastatin calcium (ROSCa), timolol maleate (TIM) and diclofenac sodium (DICNa). Method A, first derivative of ratio spectra spectrophotometric (1st DD) which is the most simple simplest one. Using the spectrum of an aliquot of 5 μg/mL of DICNa as a divisor, ROSCa could be determined by measuring [1]DD amplitudes at 239.5 and 266.5 nm for ROSCa, while TIM could be similarly determined at 307.7 and 331 nm. DICNa could be determined at 269.7 and 292 nm when 5 μg/mL aliquot of ROSCa was used as a divisor without interference. This method showed limit of detection of 0.556, 0.567 & 0.3 μg/mL and correlation coefficients of 0.9997, 0.9998 and 0.9995 for ROSCa,

_____

*Corresponding author: E-mail: mhassouna47@hotmail.com, Mohamed.hassona@science.bsu.edu.eg;

DICNa and TIM respectively. Method B, depends on subjecting the ratio spectra to mean centering (MCRS). The arithmetical description of this method was explained. The method was performed for the estimation of these drugs together in one run without preseparation in authentic laboratory prepared mixtures, bulk and spiked human plasma. The wave lengths 277.9, 313.1 and 333.12 nm were used for the quantitative estimation of each of the studied drugs with good correlation coefficients (0.9998, 0.997& 0.9999 and LOD of 0.297, 0.150 & 0.24 µg/mL for the studied drugs in the previously mentioned order. Method C, successive-ratio derivative spectra method (SRDS). The mathematical description of the method was explained. By using this method, ROSCa, TIM and DICNa could be determined at 264, 339 and 300 nm, respectively. Correlation coefficients were 0.9998, 0.9999 & 0.9995 and LOD values of 0.374, 0.258 & 0.769 µg/mL in the same order. The three methods were linear in the range 5-25 µg/mL. The obtained results has been statistically compared with those obtained by the published one, showing no significant difference regarding accuracy and precision at p = 0.05. The developed methods do not need sophisticated techniques or instruments, besides being sensitive, selective and eco-friendly.

ABBREVIATIONS

ROSCa : Rosuvastatin calcium;
TIM   : Timolol maleate;
DICNa : Diclofenac sodium;
$1^{st}DD$: First derivative of ratio spectra;
MCRS : Mean centering of ratio spectra;
SRDS : Successive-ratio derivative spectra.

1. INTRODUCTION

The chemical form of rosuvastatin calcium (ROSCa) is calcium bis [(3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(1-methyleythyl)-2-[methyl methyl sulfonyl) amino] pyrimidine-5-yl]-3,5-dihydroxyhept-6-enoate] with a chemical structure of $C_{44}H_{54}CaF_2N_6O_{12}S_2$ as shown in Fig. 1-a.

Its molecular weight is 1001 [1,2]. It has a white or almost white color and it is moisture absorbing powder, freely soluble in methylene chloride, slightly soluble in water and methanol and practically insoluble in anhydrous ethanol. It must be stored in airtight container to be protected from light at 2- 8°C [1,2].

It is available in variety of tablet forms that contain 5, 10, 20 and 40 mg of the active ingredient. It is a competitive and selective inhibitor for HMG-CoA reductase which is the responsible enzyme that converts HMG-CoA to mevalonate, which is a cholesterol forefather. ROS has proved to have high consumption and selectivity in the liver which is the organ devoted for cholesterol lowering. Its lipid modifying role is played through affecting the number of hepatic LDL receptors on the cell-surface in order to increase the consumption and decay of LDL,

thus reducing the hepatic production of VLDL, which, in turn, reduces the quantity of both LDL and VLDL.

Published literature showed that various methods have been developed for the quantitative estimation of ROSCa either individually or simultaneously including spectrophotometric [3-10], capillary electrophoresis [11], liquid chromatography (HPLC, UPLC) with UV detection or mass spectrometry [12-20], complexometric titration [21], thin layer chromatography (TLC) [22-25], electrochemical [26-28], chemometric [29] and spectrofluorimetric methods [30] have been reported for the determination of ROS–Ca in pure, dosage forms or in physiological fluids.

The chemical form of timolol maleate (TIM) is (S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol maleate(1:1) as shown in Fig. 1-b. It is white, odourless powder, has melting point of 201.5-202.5°C. Soluble 1 in 15 of water, 1 in 21 of alcohol, and 1 in 40 of chloroform; soluble in methanol; practically insoluble in ether. A 2% solution in water has a pH of 3.8 to 4.3. Ophthalmic preparations have a pH of 6.5 to 7.5. Its molecular weight equals 432.5. It is the maleate salt form of timolol, a propanolamine derivative and a non-selective beta-adrenergic antagonist with antihypertensive property. Timolol competitively binds to beta-1-adrenergic. receptors in the heart and vascular smooth muscle and beta-2-receptors in the bronchial and vascular smooth muscle, resulting in a decrease in beta-adrenergic stimulation. Its main use is in the treatment of the elevated intraocular pressure in patients who suffer

Fig. 1. Chemical structures of (a) ROSCa, (b) TIM and (c) DICNa

open-angle glaucoma or ocular hypertension [31]. TIM as a nonspecific adrenergic blocker was the first one that has been used as an antiglaucoma agent, proving more efficiency than the other newer blockers. TIM is used as anti-hypertensive agent as well [32]. It was quantitatively determined by HPLC [31-34], spectrophotometric [35,36] in bulk, pharmaceuticals and physiological fluids, UPLC methods [37] and an electrochmical one [38].

Diclofenac sodium (DICNa) is a synthetic, nonsteroidal anti-inflammatory and analgesic compound. It is odorless, white to off-white crystalline, slightly hygroscopic powder. The molecular formula of DICNa is $C_{14}H_{10}Cl_2NNaO_2$ as Fig. 1-c shows [32]. Its molecular weight equals 318.13 [39]. It is used as analgesic, anti-inflammatory and antipyretic agent. It is also used for controlling pain and ocular inflammation. It inhibits the formation of prostaglandins through the reduction of the formation of cycloxygenase enzyme. Many articles have been reported for the estimation of DICNa such as spectrophotometric [40-43], chromatographic [44-46] and electrochemical methods [47-49].

An HPLC method [32] was proposed for the determination of ROSCa, TIM and DICNa in pharmaceuticals and physiological fluids in one run. Thus, a single method has been reported for the estimation the mentioned drugs in combination. The combination of rosuvastin calcium, timolol maleate and diclofenac sodium is not official in any of the commonly known pharmacopoeias. While this combination is fruitful for the treatment of patients with multiple diseases such as hyperlipidemia, lowering the blood cholesterol, anti-hypertensive, anti-

inflammatory, analgesic and antipyretic. The selected drugs in this study are usually co-prescribed in clinical practice. So the aim of this work is to develop alternative accurate, applicable and smart first derivative of ratio spectra, mean centering of ratio spectra and successive-ratio derivative spectra methods for the simultaneous determination of ROSCa, TIM and DICNa in ternary mixture and in spiked human plasma.

2. MATERIALS AND METHODS

2.1 Chemicals and Reagents

Used chemical reagents and solvents used throughout the work were of analytical grade, such as methanol and double distilled water.

2.1.1 Pure standards

TIM and DICNa were kindly supplied by EPCI part of HIKMA group, Beni-Suef, Egypt. ROSCa was provided as a gift from SPIMACO Pharmaceutical Company, Alexandria, Egypt with claimed purity of 100.5%. The reported content of ROSCa in BP Pharmacopeia is in the range 97.0 - 102.0%.

2.1.2 Apparatus

All absorbance measurements have been performed on UV-1800 double beam UV-Visible spectrophotometer (Shimadzu-Japan) with highest resolution in which is the spectral bandwidth for the spectral range 190-1100 nm and is matched with 1 cm quartz cells. Data analysis is performed by software (UV-Probe 2.5.2). An m-file running under MATLAB R2015a

program was used for performing the data analysis of the mean centering of ratio spectra method.

2.2 Procedure

2.2.1 Preparation of standard stock solutions

1000µg/mL stock standard solutions of ROSCa, TIM and DICNa were prepared by dissolving accurately weighed 100 mg of each of them in three 100 mL volumetric flasks, add about 70 mL of methanol. Sonicate for 10 min till complete dissolution then completes to the mark with the same solvent and mix well.

The working standard solutions (100µg/mL) were prepared by appropriate dilution from stock ones. All standards were freshly prepared and stored in the refrigerator.

2.2.2 Construction of calibration curves

a) For pure standards of ROSCa, TIM and DICNa

Aliquots (1.25, 2.5, 3.75, 5 and 6.25 mL) of each of ROSCa, TIM and DICNa were transferred separately from their standard working solutions (100µg/mL) to 25-mL volumetric flasks to obtain a series of concentrations (5,10,15,20 and 25µg/mL) for each. Spectra of ROSCa, TIM and DICNa (zero order ones) are scanned in the range of 200-400 nm (Fig. 2) and stored. λ_{max} is determined for each individual drug solution. Calibration curves are plotted relating the absorbance to the corresponding concentrations of each drug.

b) For laboratory prepared mixtures

Different laboratory mixtures of the three drugs were prepared in the range 5-25 µg/mL by transferring suitable aliquots from each standard working solution to a series of 25 mL volumetric flasks with different ratios as illustrated in the first column of Table 2. Each flask was completed to the mark with methanol. After mixing well, the absorbance was recorded for each mixture against methanol as blank.

c) For spiked human plasma samples

In general, the collection of blood samples should be ethical approved and must be under the umbrella of Human Research Committee in case of human volunteers administrating the drugs, but in our case blood samples were collected from healthy human volunteers who did not administrate any drugs, then plasma samples were spiked with the studied drugs, So different volumes of each of ROSCa, TIM and DICNa were transferred from their corresponding 100µg/mL working standard solutions into three series of 25-mL measuring flasks to obtain concentrations in the range of 5-25 µg /mL of each drug. 1mL of plasma was added to each flask then was completed with methanol to the mark. Methanol in this case acts both as a solvent and a protein precipitating agent. Another series of flasks was prepared containing the three drugs with each other's in different proportions, and then 1mL of plasma was added to each flask and completed to the mark with methanol. The blank was similarly prepared but without adding the drugs.

Samples were vortex mixed well, then poured into centrifuge tubes and were centrifuged for 5 minutes at 3500 rpm, where the precipitated plasma protein separates. The clear solutions were carefully decanted to clean tubes and the spectra of the individual drugs and their mixtures were scanned simultaneously against the blank and the nominal concentration for each drug was estimated by using the corresponding regression equation.

2.3 Methods

From the zero order absorption spectra, it was noticed that the three drugs could not be determined directly due to their overlapped spectra as shown in Fig. 2. In an attempt to resolve this overlapping, 1st, 2nd derivatives and Extended Ratio Subtraction methods are applied on the spectra. But as shown in Fig. 3, the overlapping could not be resolved. Thus the following methods are proposed to overcome this overlapping problem.

2.3.1 First derivative of ratio spectra spectrophotometric method (1stDD)

In this method the stored spectrum of one of the pure drug standards is divided by that of a chosen drug divisor. Then the first derivative is obtained using suitable Δλ and scaling factor. The amplitudes of the first derivative of the ratio spectra at one maximum and one minimum for each drug are plotted against the respective concentrations and the calibration curves are constructed [50,51]. By applying this method for the determination of ROSCa, DICNa and TIM, DICNa and TIM were used as divisors separately for the determination of ROSCa. Using ROSCa

and DICNa in case of TIM and ROSCa and TIM for DICNa .The optimal Δλ =8.0 and scaling factor = 1.0. The chosen divisors are 5 µg/mL standard solutions of ROSCa, DICNa and TIM.

2.3.2 Mean Centering of Ratio Spectra Method (MCRS)

(1) Theoretical background

To clarify the expression of mean centering (MC), let considering a five-dimensional vector k [51-53]:

$$k = [6 \quad 10 \quad 2 \quad 8 \quad 4]^{T}$$

The mean vector of the vector k is

$$\bar{k} = [6 \quad 6 \quad 6 \quad 6 \quad 6]^{T}$$

The vector k can be mean centered by subtracting the mean vector ($\bar{j}$) from it as follows:

$$MC(k) = k - \bar{k} \tag{1}$$

$$MC(k) = [0 \quad 4 \quad -4 \quad 2 \quad -2]^{T}$$

Where $MC(k)$ is the mean center of the vector k.

Let n is a constant vector where

$$n = [2 \quad 2 \quad 2 \quad 2 \quad 2]^{T}$$

It is clear that if the vector *y* is multiplied by *n* (a constant number), the mean centered vector is also multiplied by *n* and also if a constant number is added to the vector *y*, the mean center of this vector is not changed.

Fig. 2. Zero order absorption spectra of 5µg/mL of each of ROSCa, TIM and DICNa mixture using methanol as a blank


(a)

(b)

(c)

Fig. 3. UV spectra of 5 µg/mL of each of ROSCa, TIM and DICNa: (a) 1st derivative spectra, (b) 2nd derivative spectra and (c) Extended ratio subtraction method

(2) Application of the MCRS method for a ternary mixture of the three drugs

Considering a mixture of the three drugs *a*, *b* and *c*. where they are compatible with each other's and Beer's low is obeyed for each drug, it can be written:

$$\text{Abs(Mix)} = \alpha_a C_a + \alpha_b C_b + \alpha_c C_c \qquad (2)$$

where Abs(Mix) is the absorbance vector of the mixture, C_a, C_b and C_c are the concentrations of *a*, b and c, and α_a, α_b and α_c are the molar absorptivity vectors of *a*, b and c, respectively.

By dividing Eq. (2) by α_c corresponding to the spectrum of a standard solution of *c* in the combination mixture of the three drugs (the zero values of α_c must not be used in the divisor for the possibility of the dividing operation), the 1st ratio spectrum can be attained as in Eq. (3):

$$X = \frac{\text{Abs(Mix)}}{\alpha_c} = \frac{\alpha_a C_a}{\alpha_c} + \frac{\alpha_b C_b}{\alpha_c} + C_c \qquad (3)$$

The mean centering of any constant equals zero, then

$$\text{MC}(C_a) = \text{MC}(C_b) = \text{MC}(C_c) = 0 \qquad (4)$$

Thus the mean centering of Eq. (3) will be as follows:

$$\text{MC}(X) = \text{MC}\left[\frac{\alpha_a C_a}{\alpha_c}\right] + \text{MC}\left[\frac{\alpha_b C_b}{\alpha_c}\right] \qquad (5)$$

The 2nd ratio spectrum can be attained by dividing Eq. (5) by $\text{MC}[\alpha_b/\alpha_c]$ corresponding to the mean centering of the ratio of the spectra of the standard solutions of *b* and c as the following equation (the zero values of $\text{MC}[\alpha_b/\alpha_c]$ must not be used in the divisor for the possibility of the dividing operation):

$$Y = \frac{\text{MC}(X)}{\text{MC}[\alpha_b/\alpha_c]} = \frac{\text{MC}[\alpha_a C_a/\alpha_c]}{\text{MC}[\alpha_b/\alpha_c]} + C_b \qquad (6)$$

The mean centering of Eq. (6) will be as follows:

$$\text{MC}(Y) = \text{MC}\left[\frac{\text{MC}(X)}{\text{MC}[\alpha_b/\alpha_c]}\right] = \text{MC}\left[\frac{\text{MC}[\alpha_a C_a/\alpha_c]}{\text{MC}[\alpha_b/\alpha_c]}\right] \qquad (7)$$

Eq. (7) extracts one of the active components to be determined (*a* in this eq.) in the solution based on that there is no interference from the other components of a ternary system (*b* and c in this mixture). Also, the concentrations of the other active components can be calculated in the same manner. It is found that there is a linear relationship between C_a in the solution and the quantity of $\text{MC}(Y)$ as Eq. (7) shows. A calibration graph could be established by plotting $\text{MC}(Y)$ versus C_a either in the standard ternary mixtures or in the standard solutions of *a*. To obtain more sensitive results, the quantity of $\text{MC}(Y)$ should be measured in correspondence with minimum or maximum wavelengths. Also, calibration curves for the other components (*b* and c) can be constructed in the same manner [51-53]. This method is applied for the determination of the concentrations of ROSCa, DICNa and TIM, respectively by substituting in these equations (eq.2 to eq.7) separately.

2.3.3 Successive Ratio-Derivative Spectra Method (SRDS)

As a step, for applying the successive ratio-derivative spectra method [54], the following equation can be obtained by taking the 1st derivative of Eq. (3) where the 1st derivative of any constant (e.g. C_a, C_b and C_c) equals to zero.

$$\frac{\mathrm{d}(X)}{\mathrm{d}\lambda} = \frac{\mathrm{d}}{\mathrm{d}\lambda}\left[\frac{\alpha_a C_a}{\alpha_c}\right] + \frac{\mathrm{d}}{\mathrm{d}\lambda}\left[\frac{\alpha_b C_b}{\alpha_c}\right] \quad (8)$$

By dividing Eq. (8) by $(\mathrm{d}/\mathrm{d}\lambda)\,[\alpha_b/\alpha_c]$ corresponding to the derivative of the ratio of the spectra of the standard solutions of *b* and c as the following equation (the zero values of $(\mathrm{d}/\mathrm{d}\lambda)\,[\alpha_b/\alpha_c]$ must not be used in the divisor for the possibility of the dividing operation):

$$Z = \frac{\mathrm{d}(X)/\mathrm{d}\lambda}{(\mathrm{d}/\mathrm{d}\lambda)[\alpha_b/\alpha_c]} = \frac{(\mathrm{d}/\mathrm{d}\lambda)[\alpha_a C_a/\alpha_c]}{(\mathrm{d}/\mathrm{d}\lambda)[\alpha_b/\alpha_c]} + C_b \quad (9)$$

Then, the 1st derivative of Eq. (9) will be as follows:

$$\frac{\mathrm{d}(Z)}{\mathrm{d}\lambda} = \frac{\mathrm{d}}{\mathrm{d}\lambda}\left[\frac{(\mathrm{d}(X)/\mathrm{d}\lambda)}{(\mathrm{d}/\mathrm{d}\lambda)[\alpha_b/\alpha_c]}\right] = \frac{\mathrm{d}}{\mathrm{d}\lambda}\left[\frac{(\mathrm{d}/\mathrm{d}\lambda)[\alpha_a C_a/\alpha_c]}{(\mathrm{d}/\mathrm{d}\lambda)[\alpha_b/\alpha_c]}\right] \quad (10)$$

Eq. (10) extracts mathematically one of the active components to be determined (*a* in this eq.) in the solution with no interference from the other components of a ternary system (*b* and c in this mixture). Also, the concentrations of the other active components can be calculated in the same manner. It is found that there is a linear relationship between C_a in the solution and the quantity of $\mathrm{d}(Z)/\mathrm{d}\lambda$ as Eq. (10) shows. A calibration graph could be established by plotting $\mathrm{d}(Z)/\mathrm{d}\lambda$ versus C_a either in the standard ternary mixtures or in the standard solutions of *a*. To obtain more sensitive results, the quantity of $\mathrm{d}(Z)/\mathrm{d}\lambda$ should be measured in correspondence with minimum or maximum wavelengths. Also, calibration curves for the other components (*b* and c) can be constructed in the same manner. In the present work, this method is used for the determination of ROSCa, DICNa and TIM respectively by substituting in these equations (eq.8 to eq.10) separately.

3. METHODS DEVELOPMENT AND OPTIMIZATION

Selection of the solvent, wavelengths and divisors is one of the key factors to adjust and develop the method, so different solvents were tried such as water, ethanol and methanol. The solvent which led to develop the most resolved spectra with maximum sensitivity and minimum noise should be chosen and the use of methanol satisfies these requirements. Also, selection of

the divisor at concentrations of 5 μg/mL of ROSCa, TIM and DICNa in 1st DD showed good recovery and selectivity.

4. RESULTS AND DISCUSSION

The main aim of this work is to develop novel, accurate, sensitive and precise spectrophotometric methods for the determination of a mixture of the three drugs viz., ROSCa, DICNa and TIM in their pure form, laboratory prepared mixtures and spiked human plasma. As mentioned previously all of the zero order, 1st and 2nd derivative spectrophotometric methods failed to achieve simultaneous determination of the three drugs due to their overlapped spectra. To overcome this problem, the 1stDD, MCRS and SRDS methods are used. For convenience, each of them will be discussed separately.

### 4.1 Applying the 1ST DD Method for the Ternary Mixture

The proposed method proved its ability to solve the overlapped spectra of the three drugs as shown in Figs. 4, 5 and 6, in which the stored zero spectra of the standards of ROSCa and TIM are divided by the spectrum of 5 μg/mL of DICNa and their first derivatives are developed using Δλ=8 and scaling factor =1.0. The amplitudes of the 1st derivative of the ratio spectra at one maximum 239.5nm, one minimum at 266.5 nm for ROSCa and one maximum at 307.7nm, one minimum at 331 nm for TIM are plotted against the corresponding concentrations of ROSCa and TIM, hence the calibration curves are constructed. Also, the spectra of the DICNa and TIM pure standards are divided by the standard spectrum of 5 μg/mL of ROSCa, then the first derivative is achieved using scaling factor = 1.0 and Δλ=8. The amplitudes of the first derivative of the ratio spectra at one maximum 269.7 nm, one minimum at 292 nm for DICNa and at one maximum at 278.7 nm, one minimum at 317 nm for TIM are plotted against the mixed concentrations of DICNa and TIM, thence calibration curves are constructed. The ratio spectra of the pure standards ROSCa and DICNa are obtained by dividing their spectra by the spectrum of 5 μg/mL of TIM and the first derivative is created using scaling factor= 1.0 and Δλ=8. Similarly, the peak amplitudes of the first derivative of the ratio spectra at one minimum 284.4 nm, one maximum at 264.7 nm for DICNa and at one maximum at 239.5nm, one minimum at 269.5 for

ROSCa are plotted versus the corresponding concentrations of DICNa and ROSCa, and then the calibration curves are constructed.

(a) ROSCa

(b) TIM

Fig. 4. Ratio spectra and first derivative of the ratio spectra of different concentrations of solution of: (a) ROSCa and (b) TIM in methanol when 5 µg/mL solution of DICNa in methanol is used as a divisor (Δλ =8 nm)


(a) DICNa

8

(b) TIM

Fig. 5. Ratio spectra and first derivative of the ratio spectra of different concentrations of solution of: (a) DICNa and (b) TIM in methanol when 5 µg/mL solution of ROSCa in methanol is used as a divisor (Δλ =8 nm)

(a) ROSCa

(b) DICNa

Fig. 6. Ratio spectra and first derivative of the ratio spectra of different concentrations of solution of :(a) ROSCa and (b) DICNa in methanol when 5 µg/mL solution of TIM in methanol is used as a divisor (Δλ =8 nm)

4.2 Applying the MCRS Method

The developed MCRS method is based on getting the MC of ratio spectra. MCRS method is performed for the determination of ROSCa, TIM and DICNa drugs in a mixture in one run without preseparation. To optimize the proposed method, different divisor concentrations were tested to develop high selective method. 5µg/mL is the most suitable concentration. The spectra of the drugs were created in the range 222-349 nm as shown in Fig. 7.

The stored spectra of different concentrations of the drugs are exported to the MATLAP program. ROSCa, TIM and DICNa concentrations in the authentic ternary mixture and in real samples could be determined by applying the equations from 2 to 7 and assuming that ROSCa is (a),TIM is (b) and DICNa is (c). From the resulted graphs of MC of second ratio spectra for the drugs as in (Fig. 8), it is found that 277.9, 313.1and 333.1 nm are the suitable wave lengths for the determination of ROSCa, TIM and DICNa, respectively. The calibration curves are constructed by plotting the measured amplitudes versus their corresponding concentrations and r2 values are computed as in Table 1.

4.3 Applying the SRDS Method

The developed SRDS method is based on getting the derivative of ratio spectra. SRDS method is applied for the determination of ROSCa, TIM and DICNa in the ternary mixtures containing these drugs. To optimize the proposed method, different divisor concentrations were tested to develop high selectivity. 5µg/mL proved as the most suitable concentration. The spectra of the drugs were created in the range 222-349 nm.

The stored spectra of different concentrations of the drugs and their mixtures are exported to the MATLAP program. ROSCa, TIM and DICNa concentration in the ternary mixture and real samples could be determined by applying the equations from 8 to 10 and assuming that ROSCa is (a), TIM is (b) and DICNa is (c). From the resulted graphs of SRDS for the drugs as in (Fig. 10), it is found that 264, 339 and 300 nm are the suitable wave lengths for the determination of ROSCa, TIM and DICNa respectively. The calibration curves are constructed by plotting the measured amplitudes versus their corresponding concentrations and r2 values are computed as in Table 1.

Fig. 7. The absorption spectra of different concentrations of ROSCa, TIM and DICNa in methanol

The Second Ratio Spectra

MC of The Second Ratio Spectra

Fig. 8. The first ratio spectra, the MC of first ratio spectra (eq.5), the second ratio spectra (eq.6) and the MC of second ratio spectra (eq.7) of ROSCa

MC of The Second Ratio Spectra

(a)

(b)

Fig. 9. (a) MC of second ratio spectra of TIM (b) MC of second ratio spectra of DICNa

(a)

(b)

(c)

Fig. 10. SRDS method for determination of (a) ROSCa (b) TIM (c) DICNa

4.4 Validation of the Analytical Method

The effectiveness of the method has been proved, according the ICH guidelines (ICH Q2R1), considering linearity, accuracy, selectivity, LOQ and LOD [55].

(1) Linearity and ranges

The linearity of the developed methods is in the concentration range (5.0-25.0µg/mL) for the three drugs. The calibration graphs are obtained by plotting the absorbance versus the corresponding known concentration. The results of the methods have good linearity as indicated by the obtained values of correlation coefficients, slope and intercept, Table 1.

(2) Quantitation (LOQ) and Detection limits (LOD)

LOQ and LOD are based on the Slope and the Standard Deviation of the blank. The analyte concentrations of the samples used for construction of a specific calibration graph should be in LOQ and LOD range. The LOQ =10 × σ /slope and LOD=3.3 × σ /slope, where σ = the standard deviation of the blank and the slope of the calibration line as clarified in Table 1.

(3) Precision

(a) Repeatability:

The intraday RSD % (n = 3), average of three concentrations (5, 10 and 15µg/mL) for each of

ROSCa, DICNa and TIM, respectively were repeated three times within the day. The good obtained results are presented in Table 1.

(b) Intermediate precision:

The Intraday RSD% (n=3), the measurements of the average of three concentrations (5, 10 and 15µg/mL) for each of ROSCa, DICNa and TIM respectively are repeated through three days successively. The obtained results are presented in Table 1.

(4) Accuracy and recovery

Accuracy of the developed methods was calculated as recoveries % of pure samples of the target drugs. Accuracy is evaluated by using three concentrations (5 & 10 & 15 µg/mL) for ROSCa, TIM and DICNa, respectively within the linear range by repeating the measurements three times. The corresponding regression equations were used for calculating concentrations. The values of the mean recoveries percent for ROSCa, TIM and DICNa are in between 98% and 102%. The data of accuracy are presented in Table 1.

(5) Selectivity

The selectivity of the developed methods for the three drugs in laboratory prepared mixtures containing them in different ratios is obtained within the linear range. The developed methods were evaluated by the analysis of laboratory

Table 1. Validation and regression parameters of the developed methods for determination of ROSCa, TIM and DICNa

Parameter	ROSCa			DICNa			TIM		
	1st DD	MCR	SRDS	1st DD	MCR	SRDS	1st DD	MCR	SRDS
Range (µg/mL)	5-25	5-25	5-25	5-25	5-25	5-25	5-25	5-25	5-25
Slope	0.018	0.021	0.025	0.237	0.014	0.159	0.039	0.029	0.0014
Intercept	0.003	0.001	0.0024	0.047	0.002	0.0148	0.003	0.0018	0.0003
Correlation coefficient	0.9997	0.9998	0.9998	0.9998	0.997	0.9999	0.9995	0.9999	0.9995
Accuracy (Mean ± RSD)	100.28±1.157	100.65±1.2	100.72±1.16	100.30± 0.84	101.09±1.61	100.31±1.103	100.26±0.87	100.24±1.12	100.17±1.36
LOD[a] (µg/mL)	0.556	0.297	0.374	0.567	1.50	0.258	0.3	0.24	0.769
LOQ[a] (µg/mL)	1.68	0.90	1.135	1.71	4.56	0.784	0.91	0.73	2.332
Intra-day*RSD%	0.121	0.159	0.173	0.295	0.14	0.21	0.031	0.003	0.195
Inter-day*RSD%	0.151	0.245	0.186	0.378	0.413	0.34	0.035	0.017	0.269
Wave lengths nm	239.5	277.9	264	269.7	333.1	300	307.7	313.1	339

[a] *Limit of detection (3.3× σ /Slope) and limit of quantization (10× σ /Slope)*

Table 2. Determination of ROSCa, TIM and DICNa in laboratory prepared mixture by applying the developed methods

Ratio of ROSCa: TIM: DICNa	ROSCa			DICNa			TIM		
	Recovery %								
	1st DD	MCRS	SRDS	1st DD	MCRS	SRDS	1st DD	MCRS	SRDS
1:1:1	101.5	101.7	98.0	99.1	99.03	98.22	98.7	98.4	98.59
2:1:1	99.1	98.8	100.1	99.3	103.1	100.25	99.7	101.3	101.1
3:2:1	101.8	100.7	100.8	99.4	93.3	100.1	100.1	99.9	102.4
4:3:2	100.5	99.3	99.18	99.5	102.4	99.71	100.3	100.1	99.34
5:4:3	99.7	100.3	99.79	99.5	100.6	99.73	99.3	100.3	100.5
Mean ± RSD	100.5 ±1.16	100.2±1.13	99.57±1.05	99.4±0.18	101.1±1.64	99.60±0.81	99.6±0.61	100.0±1.04	100.39±1.149

Average of three replications

prepared mixtures which contain dissimilar ratios of ROSCa, TIM and DICNa, besides applying the standard addition method to dosage forms. The obtained accuracy proved that the presence of excipients (microcrystalline cellulose NF, lactose monohydrate NF, tribasic calcium phosphate NF, crospovidone NF, magnesium stearate NF, hypromellose NF, triacetin NF, titanium dioxide USP, yellow ferric oxide, and red ferric oxide NF) in the pharmaceutical preparations did not interfere in their analysis of the three drugs as presented in Table 2.

(6) Statistical examination

Statistical comparison between the results obtained for investigation of ROSCa, TIM and DICNa by the suggested methods and those results achieved by the reported one for the simultaneous determination of the three drugs in a mixture [32] where the target compounds were analyzed on Hypersil BDS C(18) column (250 mm × 4.6 mm, 5 µm), applying 0.2% triethylamine) and acetonitrile (40:60, v/v), in isocratic mode as mobile phase, pH 2.75

Fig. 11. Interval plot of the proposed method and the reported method

Table 3. Statistical comparison between the obtained results of the developed methods and those gained by the reported ones (Inside the Fig.: RM [13] has changed to [32])

Summary of data					
Treatments					
	Reported method [32]	**1st DD**	**MCRS**	**SRDS**	**Total**
N	5	5	5	5	20
$\sum X$	504	494	494	494	1986
Mean	100.8	98.8	98.8	98.8	99.3
$\sum X^2$	50806	48810	48810	48810	197236
Std.Dev.	0.8367	0.8367	0.8367	0.8367	1.1743
Result details					
Source		**SS**	**df**	**MS**	
Between-treatments		15	3	5	F = 7.14286
Within-treatments		11.2	16	0.7	
Total		26.2	19		

The f-ratio value is 7.14286. The p-value is .00293. The result is significant at p < .05

Table 4. Recovery results of the developed methods in spiked plasma samples

ROSCa			DICNa			TIM		
Spiked	Found	Recovery	Spiked	Found	Recovery	Spiked	Found	Recovery
10	9.90	99	10	10.01	100.1	10	9.89	98.9
10	9.95	99.5	10	10.12	101.2	10	9.81	98.1
10	10.04	100.4	10	9.93	99.3	10	9.94	99.4
10	10.11	101.1	10	9.98	99.8	10	10.06	100.6
10	10.16	101.6	10	9.85	98.5	10	10.13	101.3
Mean	10.032	100.32	10	9.978	99.78	10	9.966	99.66
RSD	-	1.08%	-	-	1.0%	-	-	1.28%
%Error	-	0.32%	-	-	-0.22%	-	-	-0.34%

adjusted with 85% phosphoric acid at a flow rate of 1mL/min. The column oven temperature was kept at 45°C and the peak response was monitored at 284 nm after injecting a 50 µL sample into HPLC system. The results showed that there are no considerable differences between the suggested spectrophotometric methods and the reported one as Table 3 and Fig. 11 illustrates. One way ANOVA test was used to compare the capability of the developed methods for the simultaneous estimation of ROSCa, TIM and DICNa, by subjecting their results versus the obtained ones by using the reported method [32].

4.5 Application to Spiked Human Plasma

The developed and validated methods have been applied for the analysis of ROSCa, TIM and DICNa in spiked plasma samples. The recovery results were in the range 98-102% and RSD was less than 2.0% as displayed in Table 4.

5. CONCLUSION

Three novel, times saving, accurate and precise spectrophotometric techniques viz., smart first derivative of ratio spectra, mean centering of ratio spectra and successive-ratio derivative spectra methods are developed for the determination of ROSCa, TIM and DICNa simultaneously in ternary mixture in pure laboratory prepared and spiked human plasma samples. These innovative spectrophotometric methods were successfully applied for solving the overlapping spectra of the components of the ternary mixture. Good statistical results were obtained upon comparing those achieved by the developed methods with that of the reported one. Among the advantages of the developed techniques are that they neither need sophisticated instrumentation nor distinctive software; also, they could be applied for the routine examination of these drugs either in their pure bulk standards, spiked plasma samples, in laboratory prepared mixtures in quality control units and in laboratories having no HPLC instruments.

DISCLAIMER

The products used for this research are commonly and predominantly used products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

CONSENT

As per international standard or university standard written patient consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

The collection of blood samples should be ethical approved and must be under the umbrella of Human Research Committee in case of human volunteers administrating the drugs, but in our case blood samples were collected from healthy human volunteers who did not administrate any drugs, then plasma samples were spiked with the studied drugs.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. British Pharmacopoeia, Stationary Office, Medicines and Healthcare Products Regulatory Agency. 2017;2.

2. European Pharmacopeia 9th edition; 2017. Available:https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM205893

3. Ramadan AA, Mandil H, Ghazal N. Electrochemical behavior and differential pulse polarographic determination of rosuvastatin in pure form and in pharmaceutical preparations using dropping mercury electrode. International Journal of Pharmacy and Pharmaceutical Sciences. 2014;6:128-133.

4. Gupta A, Mishra P, Shah K. Simple UV Spectrophotometric determination of Rosuvastatin calcium in pure form and in pharmaceutical formulations. Journal of Chemistry. 2009;6(1):89-92.

5. Lahare RY, Phuge AN, Gite AL, Jadhav AK. A Review on Ultraviolet Spectrophotometric Determination of Rosuvastatin Calcium in Marketed Formulation. Int J Pure App Bio Sci. 2014; 2:169-174.

6. Uyar B, Celebier M, Altinoz S. Spectrophotometric Determination of Rosuvastatin Calcium in Tablets. Die Pharmazie. 2007;62(6):411-413.

7. Pandya CB, Channabasavaraj KP, Shridhara HS. Simultaneous estimation of Rosuvastatin calcium and ezetimibe in bulk and tablet dosage form by simultaneous equation method. International Journal of ChemTech Research. 2010;2(4):2140-2144.

8. Pandya N, Mashru RC. Simultaneous estimation of Rosuvastatin calcium and clopidogrel bisulfate in combined pharmaceutical formulation. International Journal of Drug formulation and Research. 2012;3:40-53.

9. Patel B, Jadav A, Solanki H, Parmar S, Parmar V, Captain A. Development and validation of derivative spectroscopic method for the simultaneous estimation of Rosuvastatin calcium and Fenofibrate in Tablet. International Journal of Pharma Research & Review. 2013;2:1-6.

10. Hassouna MEM, Abdel-Mageed AI, Salem HO. Indirect oxygen flask-atomic absorption spectrometric determination of Rosuvastatin calcium. Biomedical Journal of Scientific & Technical Research. 2017; 1:1-6.

11. Suslu I, Celebier M, Altinoz S. Determination of Rosuvastatin in Pharmaceutical Formulations by Capillary Zone Electrophoresis. Chromatographia. 2007;1:65-72.

12. Beludari MH, Prakash KV, Mohan GK. RP-HPLC method for simultaneous estimation of rosuvastatin and ezetimibe from their combination tablet dosage form. International Journal of Chemical and Analytical Science. 2013;4:205–209.

13. Hassouna MEM, Salem HO. Stability indicating new RP-HPLC method for the determination of Rosuvastatin calcium In pure and tablets dosage forms. International Journal of Applied Pharmaceutical and Biological Research. 2017;2:11-27.

14. Moid M, Afzal S, Rahim N, Ali T, Iffat W, Bashir L, Naz S. High performance liquid chromatographic method validation for determination of Rosuvastatin calcium in tablet dosage forms. Pakistan journal of pharmaceutical sciences. 2018;31:1577-1582.

15. Haq N, Shakeel F, Alanazi F, Alshora DH, Ibrahim MA. Development and validation of a green RP-HPLC method for the analysis of rosuvastatin: a step towards making liquid chromatography environmentally benign. Green Processing and Synthesis. 2018;7:160-169.

16. El-Abasawi NM, Attia KA, Abo-Serie AA, Abdel-Fattah A. Simultaneous determination of rosuvastatin and propranolol by HPLC in pharmaceutical dosage form. Analytical Chemistry Letters. 2018;8:46-53.

17. Attimarad M, Alkadham A, Almosawi MH, Venugopala KN. Development of rapid and validated RP-HPLC method for Concurrent quantification of rosuvastatin and aspirin Form solid dosage form. Indian Journal of Pharmaceutical Education and Research. 2018;52:151-158.

18. Islam SH, Alauddin M, Alam F, Anwar MR, Dewan I, Islam SA. Development and validation of stability-indicating Rp-Hplc method for simultaneous estimation of rosuvastatin and glibenclamide. World Journal Of Pharmacy And Pharmaceutical Sciences.2018;7(5):22-37.

19. Moussa BA, Hashem HM, Mahrouse MA, Mahmoud ST. A validated RP-HPLC method for the determination of rosuvastatin in presence of sacubitril/valsartan in rat plasma: Application to *in vivo* evaluation of OATP-mediated drug interaction potential between rosuvastatin

and sacubitril/valsartan. Microchemical Journal. 2018;143:31-38.

20. Geevarghese RB, Shirolkar SV. RP-HPLC method for estimation of Rosuvastatin calcium from bulk and transdermal dosage form. International Journal of Pharmaceutical Sciences and Research. 2018;9:4875-79.

21. Baldut M, Bonafede SL, Petrone L, Simionato LD, Segall AI. Development and validation of a complexometric titration method for the determination of Rosuvastatin calcium in raw material. Advances in Research. 2015;5:1-8.

22. Sane R, Kamat S, Menon S, Inamdar SR, Mote MR. Determination of Rosuvastatin calcium in its Bulk Drug and Pharmaceutical Preparations by High-Performance Thin-Layer Chromatography. Journal of Planar Chromatography-Modern TLC. 2005;18: 194-198.

23. Chaudhari BG, Patel NM, Shah PB. Determination of Simvastatin, Pravastatin Sodium and Rosuvastatin calcium in tablet Dosage Forms by HPTLC. Indian Journal of Pharmaceutical Sciences. 2007;69:130-132.

24. Devi S, Latha EP, Guptha CNK, Ramalingam P. Development and validation of HPTLC method for estimation of Rosuvastatin calcium in Bulk and pharmaceutical dosage forms. International Journal of Pharma and Bio Sciences. 2011;2:134-140.

25. Purkar AJ, Balap AR, Sathiyanarayanan L, Mahadik KR. Development and validation of HPTLC method for simultaneous determination of Rosuvastatin calcium and aspirin in its pure and pharmaceutical dosage form. International Journal of Pharmacy and Pharmaceutical Sciences. 2014;6(5):704-706.

26. Ramadan AA, Mandil H, Alshelhawi N. Spectrophotometric determination of Rosuvastatin calcium in pure form and pharmaceutical formulations by the oxidation using Iodine and formation triiodide complex in acetonitrile. International Journal of Pharmacy and Pharmaceutical Sciences. 2014;6: 579-585.

27. Silva TA, Pereira GF, Filho OF, Eguiluz KI, Salazar GR. Square-wave voltammetric determination of Rosuvastatin calcium in pharmaceutical and biological fluid samples using a cathodically pretreated boron-doped diamond electrode. Diamond and Related Materials. 2015;58:103-109.

28. Karadas-Bakirhan N, Gumustas M, Uslu B, Ozkan SA. Simultaneous determination of amlodipine besylate and Rosuvastatin calcium in binary mixtures by voltammetric and chromatographic techniques. Ionics. 2016;2:277-288.

29. Abdel-Fattah A. Mathematical simultaneous determination of Rosuvastatin calcium and propranolol hydrochloride using different chemometric techniques. Innoriginal: International Journal of Sciences. 2018;5:5-9.

30. El-Abasawi NM, Attia KAM, Abo-Serie AAM, Morshedy S, Abdel-Fattah A. Simultaneous determination of rosuvastatin and propranolol in their binary mixture by synchronous spectrofluorimetry. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2018;198: 322-330.
DOI: 10.1016/j.saa.2018.03.032.
[Epub 2018 Mar 13]

31. Chengalva P, Parameswari AS, Reddy JP. Simultaneous quantification of travoprost and timolol maleate in pharmaceutical formulation by RP-HPLC. International Journal of Pharmaceutical Sciences and Research. 2016;7:1724-1728.

32. Nasir F, Iqbal Z, Khan A, Ahmad L, Shah Y, Khan AZ, Khan S. Simultaneous determination of timolol maleate, Rosuvastatin calcium and diclofenac sodium in pharmaceuticals and physiological fluids using HPLC-UV. Journal of Chromatography B. 2011;879: 3434-3443.

33. Hassib ST, Elkady EF, Sayed RM. Simultaneous determination of timolol maleate in combination with some other anti-glaucoma drugs in rabbit aqueous humor by high performance liquid chromatography–tandem mass spectroscopy. Journal of Chromatography B. 2016;1022:109-117.

34. Boiero C, Allemandi D, Longhi M, Llabot JM. RP-HPLC method development for the simultaneous determination of timolol maleate and human serum albumin in albumin nanoparticles. Journal of Pharmaceutical and Biomedical Analysis. 2015;111:186-189.

35. Amirjani A, Bagheri M, Heydari M, Hesaraki S. Colorimetric determination of Timolol concentration based on localized

surface plasmon resonance of silver nanoparticles. Nanotechnology 2016;27: 375503.

36. Annapurna MM, Ganesh Ch S, Teja G R, Reddy GS. Multi component mode and derivative spectrophotometric methods for the simultaneous determination of timolol maleate and brimonidine tartrate. Advances in Research. 2018;12:S251-S 255.

37. Gallegos A, Peavy T, Dixon R, Isseroff RR. Development of a novel ion-pairing UPLC method with cation-exchange solid-phase extraction for determination of free timolol in human plasma. Journal of Chromatography B. 2018;1096:228-235.

38. Mohammed GI, Khraibah NH, Bashammakh AS, El-Shahawi MS. Electrochemical sensor for trace determination of timolol maleate drug in real samples and drug residues using Nafion/carboxylated-MWCNTs nanocomposite modified glassy carbon electrode. Microchemical Journal. 2018; 143:474-483.

39. Adeyeye CM, Li PK Diclofenac Sodium, Analytical Profiles of Drug Substances. 1990;19:123-144.
   Available: https://doi.org/10.1016/S0099-5428(08)60366-4

40. Khaskheli AR, Abro K, Sherazi STH, Afridi HI, Mahesar SA, Saeed M. Simpler and faster spectrophotometric determination of diclofenac sodium in tablets, serum and urine samples. Pakistan Journal of Analytical and Environmental Chemistry. 2009;10:53-58.

41. Matin AA, Farajzadeh MA, Jouyban A. A simple spectrophotometric method for determination of sodium diclofenac in pharmaceutical formulations. Il Farmaco. 2005;60:855-858.

42. Shi J, Xu M, Tang Q, Zhao K, Deng A, Li J. Highly sensitive determination of diclofenac based on resin beads and a novel polyclonal antibody by using flow injection chemiluminescence competitive immunoassay. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2018;191:1-7.

43. Darweesh SA, Khalaf HS, Al-Khalisy RS, Yaseen HM, Mahmood RM. Advancement and validation of new Derivative spectrophotometric method for individual and simultaneous estimation of Diclofenac

44. Thongchai W, Liawruangrath B, Thongpoon C, Machan T. High performance thin layer chromatographic method for the determination of diclofenac sodium in pharmaceutical formulations. Chiang Mai Journal of Science. 2006;33: 123-128.

45. Sultana N, Arayne MS, Ali SN. An Ultra-sensitive LC method for simultaneous determination of rosuvastatin, alprazolam and diclofenac sodium in API, pharmaceutical formulations and human serum by programming the detector. Journal of Analytical and Bioanalytical Techniques. 2012;3:1-6.

46. Alquadeib BT. Development and validation of a new HPLC analytical method for the determination of diclofenac in tablets. Saudi Pharmaceutical Journal: SPJ. 2019; 27:66-70.

47. Mostafavi M., Yaftian MR, Piri F, Shayani-Jam H. A new diclofenac molecularly imprinted electrochemical sensor based upon a polyaniline/reduced graphene oxide nano-composite. Biosensors and Bioelectronics. 2018;122: 160-167.

48. El-Wekil MM, Alkahtani SA, Ali HRH, Mahmoud AM. Advanced sensing nanomaterials based carbon paste electrode for simultaneous electrochemical measurement of esomeprazole and diclofenac sodium in human serum and urine samples. Journal of Molecular Liquids. 2018;262:495-503.

49. Afkhami A, Bahiraei A, Madrakian T. Gold nanoparticle/multi-walled carbon nanotube modified glassy carbon electrode as a sensitive voltammetric sensor for the determination of diclofenac sodium. Materials Science and Engineering: C. 2016;59:168-176.

50. Hassouna MEM, Abdelrahman MM, Mohamed MA. Novel spectrophotometric methods for simultaneous determination of Cefixime trihydrate and sodium benzoate in powder for oral suspension dosage form. Global Journal of Otolaryngology. 2017;12(4):555841.
   DOI: 10.19080/GJO.2017.12.55541

51. Abdelwahab NS, Abdelrahman MM, Salama FM, Ahmed AB. Determination of dimenhydrinate and cinnarizine in combined dosage form in presence of

cinnarizine impurity. European Journal of Chemistry. 2015;6:475-481.

52. Massart DL, Vandeginste BGM, Buydens LMC, Jong SDE, Lewi PJ, Smeyers-Verbeke J. Handbook of Chemometrics and Qualimetrics: Part A, Elsevier Science; 1997.

53. Afkhami A, Bahram M. Mean centering of ratio spectra as a new spectrophotometric method for the analysis of binary and ternary mixtures. Talanta. 2005;66:712-720.

54. Afkhami A, Bahram M. Successive ratio-derivative spectra as a new spectrophotometric method for the analysis of ternary mixtures. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2005;61:869-877.

55. ICH, Q2 (R1) Validation of Analytical Procedures: Text and Methodology. International conference on harmonization, Harmonized Tripartite Guideline, Geneva, Switzerland; 2005.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle4.com/review-history/53291